Ref ID: 669
Author:
Evans, E. G. V.
Author address:
Evans, egv, univ leeds,dept microbiol,phls,mycol reference lab,leeds ls2 9jt,w yorkshire,england
Full conference title:
Symposium on Lamisil: A New Measure in Antifungal Therapy in Skin and Nail Disease, at Dermatology 2000
Date: 7 April 1994
Abstract:
Terbinafine (Lamisil(R)) is a synthetic allylamine antifungal which has been shown to be fungicidal against dermatophytes and a number of yeasts and moulds. Topical application of terbinafine 1% cream has been shown to be a highly effective short-duration therapy for dermatophytosis of the skin. The aim of this multicentre, double-blind, parallel-group study was to compare the safety and efficacy of terbinafine 1% cream, applied twice daily for 1 week, with clotrimazole (Canesten(R)) 1% cream, applied twice daily for 4 weeks, in the treatment of tinea pedis.One hundred and seven patients with mycologically proven tinea pedis received 1 week of terbinafine 1% cream, followed by 3 weeks of placebo, and 104 patients received clotrimazole 1% cream for 4 weeks. Mycological cure (negative microscopy and culture) and effective treatment (mycological cure with no or minimal signs and symptoms) were assessed 4 and 6 weeks after commencing therapy.Mycological cure rates were 93.5% for terbinafine and 73.1% for clotrimazole (P=0.0001) at 4 weeks, and 97.2% for terbinafine and 83.7% for clotrimazole (P=0.001) at 6 weeks. Effective treatment rates at 4 weeks were 89.7% for terbinafine and 58.7% for clotrimazole (P=0.0001), and 89.7% for terbinafine and 73.1% for clotrimazole (P=0.002) at 6 weeks.The results show that 1 week of terbinafine b.d. is more effective than 4 weeks of clotrimazole b.d., in terms of both mycological cure and effective treatment.
Abstract Number: NULL
Conference Year: 1993
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a